Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trametinib - GENUV

Next Previous
Drug Profile

Trametinib - GENUV

Alternative Names: SNR 1611

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GENUV
  • Class 2 ring heterocyclic compounds; Amides; Antidementias; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Amyotrophic lateral sclerosis
  • No development reported Alzheimer's disease

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (PO, Tablet)
  • 28 Apr 2023 Genuv terminates a phase I/II trial in Amyotrophic lateral sclerosis (In adults, In the elderly) in South Korea (PO) due to necessary data being already collected (NCT04326283)
  • 18 Aug 2022 Pharmacodynamics data from a preclinical trial in Alzheimer's Disease released by GENUV

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top